Xenium Capital

Xenium Capital

Founded to steward the wealth generated by Ian Quinn's medical device ventures, Xenium Capital operates from County Galway as the investment vehicle for the Quinn family and its close business associates. Ian Quinn's legacy rests on Creganna Medical, the contract design and manufacturing firm he co-founded, which became a key outsourced partner for global medtech companies. After Creganna's sale to TE Connectivity in 2016, the Quinns concentrated their investment activity through Xenium. The firm is now directed by Enda Quinn, alongside long-term associates John Kehoe and Fiona O'Driscoll, reflecting a tight circle of trust built over decades of operational collaboration. Xenium's strategy centers squarely on early-stage medtech and healthcare ventures in Ireland, with a bias toward seed rounds where the firm's operational experience can de-risk technical and regulatory pathways. The firm co-invests frequently with Atlantic Bridge, another Dublin-headquartered technology investor with a dedicated University Bridge Fund and deep ties to the Irish startup ecosystem. Xenium participates primarily through direct equity and convertible instruments, avoiding broad fund-of-funds commitments in favor of concentrated, high-conviction positions. Geographic focus remains anchored in Ireland, particularly the medtech cluster around Galway, though portfolio companies often pursue US and EU market approvals, giving the firm indirect transatlantic exposure. Xenium's professional footprint is deliberately lean — directed by a small, senior team without a large analyst bench. The Quinn family also maintains a philanthropic infrastructure that mirrors its investment focus: BioInnovate Ireland, a medical device innovation fellowship modeled on Stanford Biodesign, and the Ian Quinn Centre for Health Technology Innovation, an endowed initiative dedicated to advancing healthtech research. These are structurally separate from Xenium's investment operations but share thematic alignment with the firm's deal flow. In September 2023, Enda Quinn was a featured speaker at Galway's MedTech Rising conference, reinforcing the firm's active presence in Ireland's health innovation convening circuit. Xenium's structural edge lies in its operating-company DNA. The principals are not career allocators; they are former operators who scaled a regulated manufacturing business and exited to a multinational acquirer. This gives Xenium a sourcing advantage within the Irish medtech community that pure financial investors cannot replicate — a reputation built on knowing how to build a device company, not just fund one.